EXACT SCIENCES CORP (EXAS) Stock Overview
USA - NASDAQ:EXAS - US30063P1057 - Common Stock
EXAS Key Statistics, Chart & Performance
The current stock price of EXAS is 62.685 USD. In the past month the price increased by 15.7%. In the past year, price decreased by -9.31%.
EXAS Latest News, Press Relases and Analysis
EXAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.19 | 396.47B | ||
| AMGN | AMGEN INC | 13.3 | 156.14B | ||
| GILD | GILEAD SCIENCES INC | 15.2 | 145.94B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.62 | 106.92B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.77B | ||
| ARGX | ARGENX SE - ADR | 89.45 | 50.72B | ||
| INSM | INSMED INC | N/A | 34.97B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.82B | ||
| NTRA | NATERA INC | N/A | 26.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.28 | 21.78B |
Related stock screener links
About EXAS
Company Profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Company Info
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719 US
CEO: Kevin T. Conroy
Employees: 6900
Phone: 16082845700
EXACT SCIENCES CORP / EXAS FAQ
What does EXAS do?
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Can you provide the latest stock price for EXACT SCIENCES CORP?
The current stock price of EXAS is 62.685 USD. The price decreased by -0.97% in the last trading session.
Does EXACT SCIENCES CORP pay dividends?
EXAS does not pay a dividend.
How is the ChartMill rating for EXACT SCIENCES CORP?
EXAS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is EXACT SCIENCES CORP (EXAS) stock traded?
EXAS stock is listed on the Nasdaq exchange.
Can you provide the market cap for EXACT SCIENCES CORP?
EXACT SCIENCES CORP (EXAS) has a market capitalization of 11.87B USD. This makes EXAS a Large Cap stock.
What is the outstanding short interest for EXACT SCIENCES CORP?
The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 4.26% of its float.
EXAS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS turns out to be only a medium performer in the overall market: it outperformed 65.23% of all stocks.
EXAS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EXAS. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability.
EXAS Financial Highlights
Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -5.43. The EPS decreased by -465.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.34% | ||
| ROE | -40.71% | ||
| Debt/Equity | 0.94 |
EXAS Forecast & Estimates
31 analysts have analysed EXAS and the average price target is 66.4 USD. This implies a price increase of 5.92% is expected in the next year compared to the current price of 62.685.
For the next year, analysts expect an EPS growth of 88.56% and a revenue growth 14.88% for EXAS